Valion Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | — | $780,000 | $1.2M |
| Gross profit | — | $2,000 | $287,000 |
| Operating income | -$7.9M | -$4.5M | -$8.2M |
| Operating expenses | $7.9M | $4.5M | $8.5M |
| Cost of revenue | — | $778,000 | $889,000 |
| Cash from operations | -$7.0M | -$5.7M | -$8.5M |
| Capital expenditure | $38,000 | $0 | $118,000 |
| Free cash flow | -$7.0M | -$5.7M | -$8.6M |
| Impairments | — | $0 | $0 |
| Total assets | $31.6M | $2.8M | $5.2M |
| Total liabilities | $7.4M | $272,000 | $1.6M |
Shares outstanding 3.2M · Free float 60.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.